| Literature DB >> 35538882 |
Tarun Sai David Campion1, J Oliver Daly2, Melissa Wake3,4,5, Susannah Ahern6, Joanne M Said1,3,6,7.
Abstract
BACKGROUND: Pregnancy represents a time of increased morbidity and mortality for women and their infants. Clinical quality registries (CQRs) collect, analyse and report key healthcare quality indicators for patient cohorts to improve patient care. There are limited data regarding existing CQRs in pregnancy. This scoping review aimed to: (1) identify Australian CQRs specific to pregnancy care and describe their general characteristics; and (2) outline their aims and measured outcomesEntities:
Keywords: clinical quality registry; pregnancy; quality; registry; scoping review
Mesh:
Year: 2022 PMID: 35538882 PMCID: PMC9545682 DOI: 10.1111/ajo.13540
Source DB: PubMed Journal: Aust N Z J Obstet Gynaecol ISSN: 0004-8666 Impact factor: 1.884
Inclusion and exclusion criteria to identify Australian clinical quality registries that primarily measure pregnancy specific outcomes
| Inclusion criteria | Exclusion criteria | |
|---|---|---|
| Theme |
Registries documenting pregnancy‐specific outcomes and conditions |
Registries that do not primarily focus on pregnancy and pregnancy outcomes, eg neonatal and paediatric registries with limited data about pregnancy‐specific parameters |
| Characteristics |
Registries that collect patient level data continuously from multiple sites Registries that measure predefined quality indicators Registries that report quality indicators back to treating clinicians Registries that operate fully within Australia Registries that recruited a baseline cohort of subjects and systematically followed them up at predefined timepoints |
Cohort studies where data are reported publicly but not specifically to clinicians contributing data Studies focusing on a specific research question rather than predefined quality indicators Administrative data collections that report in a cross‐sectional manner, eg perinatal data collections Drug, device and product safety registries Registries owned and operated by pharmaceutical companies |
| Reporting details |
Publication of least one report on the outcomes or protocol of the registry |
Registries that did not report in English |
Figure 1Systematic approach to determining eligible Australian clinical quality registries (CQRs) with a primary focus on pregnancy. Records from databases (1980‐2021), web searches, Australian Register of Clinical Registries and peer consultation (n = 956) were subject to inclusion and exclusion criteria. Reasons for exclusion have been detailed. Six CQRs were identified for analysis.
General characteristics of Australian clinical quality registries that primarily measure pregnancy‐specific outcomes
| Registry | Status | Established | Coverage | Central location | Funding | Patient population | Participating services |
|---|---|---|---|---|---|---|---|
| Australia and New Zealand twin‐twin transfusion syndrome registry | Inactive | 1995; ceased 1998 | National | Women and Infants Research Foundation, Perth WA | Information not available | Patients with prenatally diagnosed twin‐twin transfusion syndrome | Tertiary obstetric units in Australia and New Zealand |
| Australian Pregnancy Register (APR) for women with epilepsy and those taking anti‐epileptic drugs | Active | 1998 | National | St. Vincent's Hospital; Monash University; Royal Melbourne Hospital, Melbourne, VIC | Epilepsy Action Australia, Epilepsy Society of Australia, National Health and Medical Research Council, Royal Melbourne Hospital Neuroscience Foundation, pharmaceutical sponsors (Sanofi Aventis, Sanofi Genzyme, UCB Pharma, Eisai) |
(i) Australian women taking AEDs for any indication throughout pregnancy (91.8% of participants; 98.3% were women with epilepsy) (ii) Australian women not treated with AEDs in first half of pregnancy (8.2% of participants; 98.3% were women with epilepsy) |
(i) Healthcare professionals involved with medical management (over 50% were Australian neurologists) (ii) Relevant institutions and societies |
| National Register of Antipsychotic Medication in Pregnancy (NRAMP) | Active (Data analysis only with no new data being collected) | 2005 | National | Monash Alfred Psychiatry Research Centre, Melbourne VIC | Sponsors and donors (Janssen Cilag, Astra Zeneca, Hospira, Rotary), in‐kind support (Alfred Health and Monash University) | Australian pregnant women treated with an antipsychotic medication with a history of psychosis (schizophrenia, schizoaffective disorder, first‐episode psychosis and bipolar affective disorder with psychosis) (318 as at 2017) | Clinicians, health services and professional bodies (30 sites) |
| Australasian Maternity Outcomes Surveillance System (AMOSS) | Active | 2008 | National | University of Technology, Sydney | Initially funded by National Health and Medical Research Council; specific studies funded by varying organisations | 96% of Australian births captured, to study patients with rare pregnancy conditions | Clinicians at 260/275 Australian and 24/24 New Zealand units with >50 annual births |
| Neonatal Alloimmune Thrombocytopaenia Registry (NAIT) | Active | 2009 | National | Monash University, Melbourne VIC | Formal funding ceased in 2014; Monash University maintains site governance, ethics and case acquisition |
(i) Pregnant women who develop or have a history of neonatal alloimmune thrombocytopaenia (ii) Their children before and after birth |
(i) Clinicians from specialist units at hospitals (ii) Laboratories that perform diagnostic testing for neonatal alloimmune thrombocytopaenia |
| Diabetes in Pregnancy clinical register (DIP) | Active | 2012 | State‐wide, Northern Territory (NT) | Menzies School of Health Research, Darwin NT | Institutions (National Health and Medical Research Council, Global Alliance of Chronic Diseases, Diabetes Australia Research Program, Channel 7 Children Research Foundation, Australian Government Department of Health, Central Australia Academic Health Science network); private donations | All pregnant women residing in the NT >16 years old with type 1, type 2 or gestational diabetes | Referring health practitioner (doctor, midwife diabetes educator or Aboriginal health practitioner) |
Aims and corresponding outcomes of Australian clinical quality registries that primarily measure pregnancy‐specific outcomes
| Registry | Aims | Outcomes measured |
|---|---|---|
| Australia and New Zealand twin‐twin transfusion syndrome registry |
(i) To study the antenatal course and perinatal outcomes of twin‐twin transfusion registry in a large population (ii) To assess contemporary management strategies and outcomes in prenatally identified cases of twin‐twin transfusion syndrome |
(i) Gestation at diagnosis and delivery (ii) Oligohydramnios‐polyhydramnios sequence (iii) Fetal hydrops (iv) Use of therapeutic amnioreduction (iii) Birthweight of donor and recipient twin (ii) Cord haemoglobin difference between donor and recipient twin (g/L) (iv) Fetal death in utero (v) Neonatal death (vi) Perinatal survival |
| National Register of Antipsychotic Medication in Pregnancy (NRAMP) |
(i) To provide a better understanding of antipsychotic medication use during pregnancy, birth and for the first year of the baby's life (ii) To allow development of evidence‐based guidelines for the best use and effect of antipsychotic medication during pregnancy, birth and the postnatal phase (iii) Assist healthcare professionals, and women with mental illness, to make informed decisions about appropriate treatment options, and encourage safer outcomes for both mother and baby, during pregnancy, birth and the postnatal phase (iv) Enhance our knowledge regarding the care of women with mental illness during pregnancy, birth and the postnatal phase |
(i) Demographics and family history (ii) Physical health (iii) Psychiatric information and medication (iv) Rating scales (Positive and Negative Symptom Scale (v) Obstetric details (vi) Birth outcomes including APGAR scores (vii) Child outcomes including developmental milestones (viii) Maternal outcome including Mothering Attitudes Questionnaire |
| Australian Pregnancy Register (APR) for women with epilepsy and those taking anti‐epileptic drugs |
(i) To evaluate the incidence of adverse fetal outcomes resulting from pregnancies exposed to AEDs (ii) To determine if certain AEDs or combinations are associated with a higher incidence or specific types of adverse pregnancy outcomes (iii) To determine the influence of the seizures, the epilepsy type, the genetic background and environmental factors (iv) To study the comparative efficacy of AEDs on seizure protection in pregnancy, assessed on the basis of self‐reporting and increased dose or additional drug requirements |
(i) Maternal health status (particular focus on seizure control) (ii) Pregnancy outcomes (current and previous): live births; stillbirths; abortions (iii) Fetal outcomes: no defects; malformations categorised according to Victorian Birth Defect Classification. Examples identified from analysis of 20 years of registry data (spina bifida, cardiac malformations, digits, skull bones and brain, hypospadias, urinary tract malformations) |
| Australasian Maternity Outcomes Surveillance System (AMOSS) |
To study severe and often rare maternal conditions in pregnancy, childbirth and six weeks after birth using a clinical and population approach to improve safety and quality of maternity care in Australia and New Zealand by: (i) development of evidence‐based information on severe maternal morbidity (ii) use of developed information in clinical care, service planning and for patient information | Cumulative list of outcomes since AMOSS' inception defined by consultation with AMOSS project board, advisory group, collaborators, stakeholders and consumers; only few rare outcomes (<1:1000 incidence) being studied at any given time as part of cohort studies lasting 1–2 years
(i) In utero exposure to breast cancer treatment (ii) Pregnancy outcomes after breast cancer diagnosis (ii) Patient experiences
Vasa previa Morbid obesity Cardiac disease in pregnancy Placenta accreta Vasa previa; women's experiences Impact of socioeconomic status on maternal morbidity Influenza outcomes Antenatal pulmonary embolism Peripartum hysterectomy Amniotic fluid embolism |
| Neonatal Alloimmune Thrombocytopaenia Registry (NAIT) |
(i) To provide the opportunity to more accurately define incidence, natural history and clinical outcomes of neonatal alloimmune thrombocytopaenia (ii) To explore range of treatment approaches, clinical and laboratory factors that influence outcomes (iii) To better define optimal management of NAIT patients (iv) To inform and inspire future hypothesis‐driven research |
(i) Diagnoses (ii) Clinical and laboratory and imaging results (iii) Therapy (iv) Complications of disease and therapy (v) Transfusion (intravenous immunoglobulin and platelets) (vi) Clinical outcomes |
| Diabetes in Pregnancy Clinical Register (DIP) |
(i) Improve management of women with diabetes in pregnancy by improving coordination of care and centrally collating information between primary and tertiary systems (ii) Improve follow up of women with DIP (iii) To act as a quality assurance tool (iv) To be used as an epidemiological tool to highlight the burden of DIP and variability over time, place and ethnicity |
(i) Number of pregnancies, type, births (ii) Maternal indigenous status, ethnicity (iii) Location, ultrasound details, smoking and alcohol outcomes
(ii) Average glycated haemoglobin concentration (HbA1C %) with median gestation
(i) Number of births according to type of diabetes (ii) Livebirths, stillbirths (iii) Mode of delivery
(i) Neonatal deaths (ii) Birthweight, gestational age (iii) Congenital malformations (iv) Miscarriage/abortion |